Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH

Canadian Journal of Gastroenterology and Hepatology

Volumn 2016, Issue , 2016, Pages

  Wan, Xingyong ^a   Xu, Chengfu ^a   Yu, Chaohui ^a   Li, Youming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; NLRP3 PROTEIN, HUMAN;

DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; LIVER; METABOLISM; PATHOLOGY;

DISEASE PROGRESSION; HUMANS; INFLAMMASOMES; LIVER; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84971232291     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2016/6489012     Document Type: Review

References (70)

1. J. M. Clark, F. L. Brancati, and A. M. Diehl, The prevalence and etiology of elevated aminotransferase levels in the United States, The American Journal of Gastroenterology, vol. 98, no. 5, pp. 960-967, 2003.
2. D. G. Tiniakos, M. B. Vos, and E. M. Brunt, Nonalcoholic fatty liver disease: pathology and pathogenesis, Annual Review of Pathology: Mechanisms of Disease, vol. 5, pp. 145-171, 2010.
3. H. Tilg and A. R. Moschen, Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis, Hepatology, vol. 52, no. 5, pp. 1836-1846, 2010.
4. S. E. Mahady and J. George, Management of nonalcoholic steatohepatitis: An evidence-based approach, Clinical Liver Disease, vol. 16, no. 3, pp. 631-645, 2012.
5. C. P. Day and O. F. W. James, Steatohepatitis: A tale of two Hits Gastroenterology, vol. 114, no. 4, pp. 842-845, 1998.
6. C. P. Day, Pathogenesis of steatohepatitis, Bailliere's Best Practice and Research in Clinical Gastroenterology, vol. 16, no. 5, pp. 663-678, 2002.
7. A. J. Sanyal, C. Campbell-Sargent, F. Mirshahi et al., Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities, Gastroenterology, vol. 120, no. 5, pp. 1183-1192, 2001.
8. G. Szabo and T. Csak, Inflammasomes in liver diseases, Journal of Hepatology, vol. 57, no. 3, pp. 642-654, 2012.
9. E. Benetti, F. Chiazza, N. S. A. Patel, and M. Collino, The NLRP3 inflammasome as a novel player of the intercellular crosstalk in metabolic disorders, Mediators of Inflammation, vol. 2013, Article ID 678627, 9 pages, 2013.
10. T. Strowig, J. Henao-Mejia, E. Elinav, and R. Flavell, Inflammasomes in health and disease, Nature, vol. 481, no. 7381, pp. 278-286, 2012.
11. T. Csak, M. Ganz, J. Pespisa, K. Kodys, A. Dolganiuc, and G. Szabo, Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells, Hepatology, vol. 54, no. 1, pp. 133-144, 2011.
12. T. Matsuzaka, A. Atsumi, R. Matsumori et al., Elovl6 promotes nonalcoholic steatohepatitis, Hepatology, vol. 56, no. 6, pp. 2199-2208, 2012.
13. A. Wree, M. D. McGeough, C. A. Peña et al., NLRP3 inflammasomeactivation is required for fibrosis development inNAFLD, Journal of Molecular Medicine, vol. 92, no. 10, pp. 1069-1082, 2014.
14. K. Isoda, S. Sawada, M. Ayaori et al., Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice, Journal of Biological Chemistry, vol. 280, no. 8, pp. 7002-7009, 2005.
15. R. P. Witek, W. C. Stone, F. G. Karaca et al., Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis, Hepatology, vol. 50, no. 5, pp. 1421-1430, 2009.
16. Q. M. Anstee, D. Concas, H. Kudo et al., Impact of pan-caspase inhibition in animal models of established steatosis and nonalcoholic steatohepatitis, Journal of Hepatology, vol. 53, no. 3, pp. 542-550, 2010.
17. K. Miura, Y. Kodama, S. Inokuchi et al., Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1 in mice, Gastroenterology, vol. 139, no. 1, pp. 323-334. e7, 2010.
18. Y. Kamari, A. Shaish, E. Vax et al., Lack of interleukin-1 or interleukin-1 inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice, Journal of Hepatology, vol. 55, no. 5, pp. 1086-1094, 2011.
19. R. Stienstra, J. A. van Diepen, C. J. Tack et al., Inflammasome is a central player in the induction of obesity and insulin resistance, Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 37, pp. 15324-15329, 2011.
20. B. Vandanmagsar, Y.-H. Youm, A. Ravussin et al., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance, Nature Medicine, vol. 17, no. 2, pp. 179-188, 2011.
21. L. J. Dixon, M. Berk, S. Thapaliya, B. G. Papouchado, and A. E. Feldstein, Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis, Laboratory Investigation, vol. 92, no. 5, pp. 713-723, 2012.
22. J. Pihlajamäki, T. Kuulasmaa, D. Kaminska et al., Serum interleukin 1 receptor antagonist as an independent marker of nonalcoholic steatohepatitis in humans, Journal of Hepatology, vol. 56, no. 3, pp. 663-670, 2012.
23. L. J. Dixon, C. A. Flask, B. G. Papouchado, A. E. Feldstein, and L. E. Nagy, Caspase-1 as a central regulator of high fat dietinduced non-alcoholic steatohepatitis, PLoS ONE, vol. 8, no. 2, Article ID e56100, 2013.
24. F. J. Barreyro, S. Holod, P. V. Finocchietto et al., The pancaspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in amurinemodel of non-alcoholic steatohepatitis, Liver International, vol. 35, no. 3, pp. 953-966, 2015.
25. B. A. Neuschwander-Tetri, Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites, Hepatology, vol. 52, no. 2, pp. 774-788, 2010.
26. M. Fuchs and A. J. Sanyal, Lipotoxicity in NASH, Journal of Hepatology, vol. 56, no. 1, pp. 291-293, 2012.
27. W. Peverill, L. W. Powell, and R. Skoien, Evolving concepts in the pathogenesis ofNASH: beyond steatosis and inflammation, International Journal of Molecular Sciences, vol. 15, no. 5, pp. 8591-8638, 2014.
28. A. Wree, L. Broderick, A. Canbay, H. M. Hoffman, and A. E. Feldstein, From NAFLD to NASH to cirrhosis-new insights into diseasemechanisms, Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 11, pp. 627-636, 2013.
29. P. Puri, R. A. Baillie, M. M. Wiest et al., A lipidomic analysis of nonalcoholic fatty liver disease, Hepatology, vol. 46, no. 4, pp. 1081-1090, 2007.
30. J. Araya, R. Rodrigo, L. A. Videla et al., Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease, Clinical Science, vol. 106, no. 6, pp. 635-643, 2004.
31. R. Loomba, O. Quehenberger, A. Armando, and E. A. Dennis, Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis, Journal of Lipid Research, vol. 56, no. 1, pp. 185-192, 2015.
32. M. Lazic, M. E. Inzaugarat, D. Povero et al., Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis, PLoS ONE, vol. 9, no. 9, Article ID e107658, 2014.
33. M. F. Abdelmalek, A. Suzuki, C. Guy et al., Increased fructose consumption is associatedwith fibrosis severity in patientswith nonalcoholic fatty liver disease, Hepatology, vol. 51, no. 6, pp. 1961-1971, 2010.
34. S. Zelber-Sagi, D. Nitzan-Kaluski, R. Goldsmith et al., Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study, Journal of Hepatology, vol. 47, no. 5, pp. 711-717, 2007.
35. X. Ouyang, P. Cirillo, Y. Sautin et al., Fructose consumption as a risk factor for non-alcoholic fatty liver disease, Journal of Hepatology, vol. 48, no. 6, pp. 993-999, 2008.
36. C. Savard, E. V. Tartaglione, R. Kuver et al., Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis, Hepatology, vol. 57, no. 1, pp. 81-92, 2013.
37. G. N. Ioannou, O. B. Morrow, M. L. Connole, and S. P. Lee, Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population, Hepatology, vol. 50, no. 1, pp. 175-184, 2009.
38. G. N. Ioannou, D. M. Van Rooyen, C. Savard et al., Cholesterollowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH, Journal of Lipid Research, vol. 56, no. 2, pp. 277-285, 2015.
39. G. N. Ioannou, W. G. Haigh, D. Thorning, and C. Savard, Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis, Journal of Lipid Research, vol. 54, no. 5, pp. 1326-1334, 2013.
40. S. Sookoian and C. J. Pirola, Meta-analysis of the influence of I148Mvariant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease, Hepatology, vol. 53, no. 6, pp. 1883-1894, 2011.
41. S. Romeo, J. Kozlitina, C. Xing et al., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nature Genetics, vol. 40, no. 12, pp. 1461-1465, 2008.
42. A.-C. Tosello-Trampont, S. G. Landes, V. Nguyen, T. I. Novobrantseva, and Y. S. Hahn, Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-inducedmouse model through tumor necrosis factor production, The Journal of Biological Chemistry, vol. 287, no. 48, pp. 40161-40172, 2012.
43. W.-K. Syn, K. M. Agboola, M. Swiderska et al., NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease, Gut, vol. 61, no. 9, pp. 1323-1329, 2012.
44. W. K. Syn, Y. H. Oo, T. A. Pereira et al., Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease, Hepatology, vol. 51, no. 6, pp. 1998-2007, 2010.
45. V. L. Gadd, R. Skoien, E. E. Powell et al., The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease, Hepatology, vol. 59, no. 4, pp. 1393-1405, 2014.
46. S. Sutti, A. Jindal, I. Locatelli et al., Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH, Hepatology, vol. 59, no. 3, pp. 886-897, 2014.
47. K. Kawasaki, M. Abe, F. Tada et al., Blockade of B-cellactivating factor signaling enhances hepatic steatosis induced by a high-fat diet and improves insulin sensitivity, Laboratory Investigation, vol. 93, no. 3, pp. 311-321, 2013.
48. Y. S. Roh and E. Seki, Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis, Journal of Gastroenterology and Hepatology, vol. 28, supplement 1, pp. 38-42, 2013.
49. M. Ganz and G. Szabo, Immune and inflammatory pathways in NASH, Hepatology International, vol. 7, supplement 2, pp. 771-781, 2013.
50. K. Miura, L. Yang, N. van Rooijen, D. A. Brenner, H. Ohnishi, and E. Seki, Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice, Hepatology, vol. 57, no. 2, pp. 577-589, 2013.
51. J. A. Ehses, D. T. Meier, S. Wueest et al., Toll-like receptor 2-deficient mice are protected frominsulin resistance and beta cell dysfunction induced by a high-fat diet, Diabetologia, vol. 53, no. 8, pp. 1795-1806, 2010.
52. G. Szabo, A. Velayudham, L. Romics Jr., and P. Mandrekar, Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: The role of toll-like receptors 2 and 4, Alcoholism: Clinical and Experimental Research, vol. 29, no. 11, pp. 140s-145s, 2005.
53. C. A. Rivera, L. Gaskin, M. Allman et al., Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis, BMC Gastroenterology, vol. 10, article 52, 2010.
54. L. Li, L. Chen, L. Hu et al., Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice, Hepatology, vol. 54, no. 5, pp. 1620-1630, 2011.
55. C. A. Rivera, P. Adegboyega, N. van Rooijen, A. Tagalicud, M. Allman, and M. Wallace, Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of nonalcoholic steatohepatitis, Journal of Hepatology, vol. 47, no. 4, pp. 571-579, 2007.
56. D. Ye, F. Y. L. Li, K. S. L. Lamet al., Toll-like receptor-4mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice, Gut, vol. 61, no. 7, pp. 1058-1067, 2012.
57. J. Liu, Z.-J. Zhuang, D.-X. Bian et al., Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice, Clinical and Experimental Pharmacology and Physiology, vol. 41, no. 7, pp. 482-488, 2014.
58. S. Kiziltas, P. Ata, Y. Colak et al., TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls, Metabolic Syndrome and Related Disorders, vol. 12, no. 3, pp. 165-170, 2014.
59. T. Csak, A. Pillai, M. Ganz et al., Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in aMyD88-dependentmanner in dietary steatohepatitis, Liver International, vol. 34, no. 9, pp. 1402-1413, 2014.
60. G. Szabo, S. Bala, J. Petrasek, and A. Gattu, Gut-liver axis and sensing microbes, DigestiveDiseases, vol. 28, no. 6, pp. 737-744, 2010.
61. L. Miele, G. Marrone, C. Lauritano et al., Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target, Current Pharmaceutical Design, vol. 19, no. 29, pp. 5314-5324, 2013.
62. K. Miura, E. Seki, H. Ohnishi, and D. A. Brenner, Role of tolllike receptors and their downstream molecules in the development of nonalcoholic fatty liver disease, Gastroenterology Research and Practice, vol. 2010, Article ID362847, 9 pages, 2010.
63. A. Farhadi, S. Gundlapalli, M. Shaikh et al., Susceptibility to gut leakiness: A possible mechanism for endotoxaemia in nonalcoholic steatohepatitis, Liver International, vol. 28, no. 7, pp. 1026-1033, 2008.
64. A. Velayudham, A. Dolganiuc, M. Ellis et al., VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice, Hepatology, vol. 49, no. 3, pp. 989-997, 2009.
65. N. Xie, Y. Cui, Y.-N. Yin et al., Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet, BMC Complementary and Alternative Medicine, vol. 11, article 53, 2011.
66. S. Olteanu, M. Kandel-Kfir, A. Shaish et al., Lack of interleukin-1 in Kupffer cells attenuates liver inflammation and expression of inflammatory cytokines in hypercholesterolaemic mice, Digestive and Liver Disease, vol. 46, no. 5, pp. 433-439, 2014.
67. W. Wang, C. Wang, X.-Q. Ding et al., Quercetinandallopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats, British Journal of Pharmacology, vol. 169, no. 6, pp. 1352-1371, 2013.
68. H. Wen, D. Gris, Y. Lei et al., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling, Nature Immunology, vol. 12, no. 5, pp. 408-415, 2011.
69. J. Henao-Mejia, E. Elinav, C. Jin et al., Inflammasomemediated dysbiosis regulates progression of NAFLD and obesity, Nature, vol. 482, no. 7384, pp. 179-185, 2012.
70. V. Ratziu, M. Y. Sheikh, A. J. Sanyal et al., A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis, Hepatology, vol. 55, no. 2, pp. 419-428, 2012.